Sigilon Therapeutics

Sigilon Therapeutics, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutic treatments for a wide range of chronic diseases. Its program includes Rare Blood Disorders, Lysosomal Storage Diseases, and Endocrine and Other Chronic Diseases. The company was founded by Daniel G. Anderson, Robert S. Langer Jr., Jose Oberholzer, Arturo Vegas, and Omid Veiseh on May 14, 2015 and is headquartered in Cambridge, MA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sigilon Therapeutics is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases. To address these therapy problems, Sigilon is developing its Shielded Living TherapeuticsTM platform. Sigilon is designing product candidates to provide a wide range of functions or therapeutic molecules that may be missing or deficient in the body, leveraging advances in cell differentiation and engineering, as well as cutting-edge innovations in its proprietary biocompatible materials—potentially resulting in functional cures for patients with a wide range of acute and chronic diseases.

Eli Lilly

INDIANAPOLIS , Aug. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Sigilon Therapeutics, Inc. (NASDAQ: SGTX). The acquisition allows Lilly to continue researching and developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes.

Lilly Completes Acquisition of Sigilon Therapeutics

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sigilon Therapeutics, Inc. (NasdaqGS: SGTX) to Eli Lilly and Company (NYSE: LLY). Under the terms of the proposed transaction, shareholders of Sigilon will receive $14.92 in cash, plus one non-tradeable contingent value right that entitles the holder to receive up to an additional $111.64 per share, for each s.

SIGILON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sigilon Therapeutics, Inc. - SGTX

Eli Lilly (LLY) is set to acquire Sigilon (SGTX) for $14.92 per share, in cash, along with a contingent value right of $111.64 per share.

Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli Lilly

Shares of Sigilon Therapeutics Inc (NASDAQ: SGTX) soared more than 500% today after Eli Lilly & Co (NYSE: LLY) said it will buy the biopharmaceutical company in a deal worth up to $309.6 million. Details of the Lilly-Sigilon agreement Lilly has agreed to pay a total of up to $126.

Eli Lilly to buy Sigilon Therapeutics on a massive premium

Eli Lilly said it will acquire Sigilon Therapeutics in an all-cash deal worth up to $309.6 million.

Eli Lilly to Acquire Sigilon Therapeutics

MILWAUKEE , June 29, 2023 /PRNewswire/ -- Ademi LLP is investigating Sigilon (Nasdaq: SGTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Eli Lilly.  Click here to learn how to join the action https://www.ademilaw.com/case/sigilon-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Sigilon Therapeutics, Inc. has obtained a Fair Price in its transaction with Eli Lilly

Eli Lilly said Thursday it will buy its diabetes treatment partner, Sigilon Therapeutics, and the biotech stock skyrocketed.

Sigilon Therapeutics Scores Eli Lilly Buyout And Skyrockets More Than 500%

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Sigilon Therapeutics, Inc. (NASDAQ: SGTX) to Eli Lilly and Company is fair to Sigilon shareholders. Under the terms of the agreement, Eli Lilly would acquire all outstanding shares of Sigilon for $14.92 per share in cash payable at closing, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $111.64 per share in cash. Halper S.

SGTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Sigilon Therapeutics, Inc. Is Fair to Shareholders

Eli Lilly and Co said on Thursday it will acquire all the shares of Sigilon Therapeutics that it did not own to gain access to experimental cell therapies that can provide longer-term solutions for diabetes patients.

Eli Lilly to buy Sigilon Therapeutics to expand diabetes treatments

Sigilon Therapeutics (NASDAQ: SGTX ) stock is rocketing on Thursday morning after Eli Lilly (NYSE: LLY ) agrees to acquire the company. The acquisition will see Eli Lilly pay $14.92 per share in cash and one tradeable contingent value right for each share of SGTX stock.

Why Is Sigilon Therapeutics (SGTX) Stock Up 691% Today?

Eli Lilly & Co. LLY, -1.25% said Thursday it has agreed to acquire Sigilon Therapeutics in a deal worth up to $309.6 million, sending Sigilon's stock up more than 470% premarket. Under the terms of the deal, Lilly will pay $14.92 per Sigilon share in cash, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $111.64 per share in cash, for a total potential consideration of up to $126.56 per share in cash without interest.

Sigilon Therapeutics' stock soars 472% after Eli Lilly agrees to acquire company

INDIANAPOLIS and CAMBRIDGE, Mass. , June 29, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced a definitive agreement for Lilly to acquire Sigilon, a biopharmaceutical company that seeks to develop functional cures for patients with a broad range of acute and chronic diseases.

Lilly to Acquire Sigilon Therapeutics

CAMBRIDGE, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced it will effect a one-for-13 reverse stock split of its issued and outstanding common stock. Sigilon stockholders approved an amendment to Sigilon's Fifth Amended and Restated Certificate of Incorporation to effect the reverse stock split at Sigilon's Annual Meeting of Stockholders held on May 19, 2023. The reverse stock split is intended to increase the per share trading price of Sigilon's common stock to enable Sigilon to satisfy the minimum price requirement for continued listing on the Nasdaq Global Select Market. Sigilon expects that upon the opening of trading on May 23, 2023, its common stock will trade on the Nasdaq Global Select Market on a split-adjusted basis under the current trading symbol “SGTX” and the CUSIP number 82657L206.

Sigilon Announces Reverse Stock Split of Common Stock

SIG-002, Sigilon's lead program for the treatment of diabetes, transitioning to IND-enabling and NHP studies in the second half of 2023

Sigilon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Vericel

CHICAGO , May 2, 2023 /PRNewswire/ -- Dimension Inx, a biomaterials platform company developing therapeutics that restore tissue and organ function, announced today the appointments of Paul K. Wotton, Ph.D.

Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D.

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop functional cures for acute and chronic diseases through its Shielded Living Therapeutics™ platform, today announced that its President and Chief Executive Officer, Rogerio Vivaldi, M.D., will present a corporate overview during the Needham Virtual Healthcare Conference. The presentation will take place on Thursday, April 20, 2023 at 10:15 a.m. EDT.

Sigilon Therapeutics to Present at the Needham Virtual Healthcare Conference

Bright Green Corp

Chembio Diagnostics

Healthcare Triangle

Hepion Pharmaceuticals Inc

Hillstream Biopharma

Magenta Therapeutics Inc

Spectrum Pharma

The healthcare sector has more high return generating companies than many other sectors.

10 Best-Performing Penny Stocks in the Health Care Sector

Advancing IND-enabling activities for lead program in diabetes, SIG-002, with plans to conduct non-human primate studies in second half of 2023

Sigilon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Kytopen, an MIT-spin out and biotechnology company leading advancements in high-throughput cellular and genome engineering platforms, today announced it is assembling a group of experts in the diverse fields of immunology, synthetic biology, engineering, and manufacturing for its newly formed Scientific Advisory Board (SAB). The SAB will provide technical and strategic guidance for ongoing research and development programs at Kytopen and influence plans for both current and future innovations. The Board will collaborate with Kytopen scientists, engineers, and leadership towards realizing Kytopen's mission to expand patients' access to engineered living medicines.

Kytopen Announces Foundation of New Scientific Advisory Board Joined by Cullen Buie, Ph.D., Omid Veiseh, Ph.D.

Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of 37.21% and 73.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Sigilon Therapeutics, Inc. (SGTX) Reports Q3 Loss, Tops Revenue Estimates

Identified important optimization features for its platform to mitigate PFO risks in current and future programs

Sigilon Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of 4.35% and 22.68%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sigilon Therapeutics, Inc. (SGTX) Reports Q2 Loss, Tops Revenue Estimates

Company expects to report results of preclinical MPS-1 studies in second half of 2022 to inform pipeline strategy Company expects to report results of preclinical MPS-1 studies in second half of 2022 to inform pipeline strategy

Sigilon Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

Sigilon Therapeutics, Inc. (SGTX) delivered earnings and revenue surprises of -43.33% and 27.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Sigilon Therapeutics, Inc. (SGTX) Reports Q1 Loss, Tops Revenue Estimates

On track to announce results from preclinical studies of SIG-005 in second half of 2022

News for Sigilon Therapeutics Stock (SGTX)